over $1, page-7

Exactly right Drafter. BLT is a platform company not a one trick pony. Indeed even positive Calimmune results and Gradalis results will validate the technology as a whole. HCV results, if positive, and a pharma deal will set a financial foundation to open up all the other applications for ddRNAi and it is then that we will see revaluation upon revaluation upwards as the astonishing potential for the entire platform becomes realised.